VADS
INDUCE-3 (GSK-209229)
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3)
Paris
CHRISTOPHE LE TOURNEAU
VADS
INDUCE-4 (GSK-209227)
A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Paris
CHRISTOPHE LE TOURNEAU
Appareil Digestif
AMEBICA - Prodige 38
Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours.
Saint-Cloud
Hématologie Leucémie
AML LI-1
A PROGRAMME OF DEVELOPMENT FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME
Saint-Cloud
JACQUES VARGAFTIG
Appareil Digestif
PACHA 01
Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial
Saint-Cloud